Clinical Trial

Cohort for Monitoring Patients With Venous Thromboembolic Disease

Study acronym: CoMTEV
Recruiting
View on ClinicalTrials.gov →
Summary
Venous thromboembolic disease is a common pathology in the general population (1.5/1000), the prognosis of which depends in particular on the risk of recurrence. This risk depends essentially on whether the thrombotic episode was provoked or not. Thus, patients who present a thromboembolic event without any contributing factor have a high risk of recurrence, which encourages clinicians to continue anticoagulant treatment for a long time. However, anticoagulant treatment is the leading cause of hospitalization for iatrogenic causes and the leading cause of iatrogenic mortality. The benefit-risk balance of treatment must be evaluated regularly, which requires a good knowledge of the risk factors for thrombotic recurrence and the risk factors for hemorrhage.
Trial Details
NCT Number NCT07016542
Lead Sponsor University Hospital, Rouen
Conditions Venous Thromboembolic Disease
Enrollment 2,000 participants
Start Date 2019-11-18
Primary Completion 2031-12-01 (estimated)
Study Completion 2032-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-11